Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{186295,
        author = {Mr. Mujeeb Muhamadhusen Shaikh and Mustafa Mushala and Seher Momin},
        title = {AI AND THE GLOBAL DRUG DIVIDE: ETHICAL AND ACCESS CHALLENGES IN PHARMACEUTICAL R&D.},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {924-925},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=186295},
        abstract = {Artificial intelligence (AI) is rapidly transforming pharmaceutical research and development (R&D), enabling faster drug discovery, predictive modeling, and personalized therapies. While these advancements promise unprecedented improvements in healthcare, their benefits are unevenly distributed. AI-driven R&D predominantly benefits high-income countries with robust digital infrastructures and extensive health data, creating a global drug divide. Ethical concerns arise regarding data privacy, transparency, algorithmic bias, and equitable access to therapies. This review explores AI's role in pharmaceutical innovation, highlights the challenges of global inequity, and examines strategies for democratizing access to AI-driven medicines. Ultimately, it raises a critical question: how can AI innovations be harnessed to serve populations worldwide, not just the privileged few?},
        keywords = {},
        month = {November},
        }